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Abstract
Background: In spite of the significant mortality associated with Plasmodium falciparum infection, the mechanisms
underlying severe disease remain poorly understood. We have previously shown evidence of endothelial activation in
Ghanaian children with malaria, indicated by elevated plasma levels of both von Willebrand factor (VWF) and its propeptide.
In the current prospective study of children in Malawi with retinopathy confirmed cerebral malaria, we compared these
markers with uncomplicated malaria, non malarial febrile illness and controls.
Methods and Findings: Children with cerebral malaria, mild malaria and controls without malaria were recruited into the
study. All comatose patients were examined by direct and indirect ophthalmoscopy. Plasma VWF and propeptide levels
were measured by ELISA. Median VWF and propeptide levels were significantly higher in patients with uncomplicated
malaria than in children with non-malarial febrile illness of comparable severity, in whom levels were higher than in non-
febrile controls. Median concentrations of both markers were higher in cerebral malaria than in uncomplicated malaria, and
were similar in patients with and without retinopathy. Levels of both VWF and propeptide fell significantly 48 hours after
commencing therapy and were normal one month later.
Conclusions: In children with malaria plasma VWF and propeptide levels are markedly elevated in both cerebral and mild
paediatric malaria, with levels matching disease severity, and these normalize upon recovery. High levels of both markers
also occur in retinopathy-negative ‘cerebral malaria’ cases, many of whom are thought to be suffering from diseases other
than malaria, indicating that further studies of these markers will be required to determine their sensitivity and specificity.
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Introduction
Falciparum malaria is one of the commonest potentially fatal
infections in sub-Saharan Africa. Most deaths from malaria occur
in young children living in areas of intense Plasmodium falciparum
transmission. African children bear 90% of the brunt of mortality
from falciparum malaria, with high case fatality rates in children
with cerebral malaria even with good treatment [1]. Falciparum
malaria is a major cause of morbidity and mortality in Malawi
particularly in children under the age of five. More than 40% of
in-hospital deaths in Malawian children are attributed to malaria,
and cerebral malaria is a common manifestation of severe and
complicated malaria [2]. Children in Blantyre district, where
transmission is stable and intense, suffer on average 2.8
symptomatic malaria episodes per year while adults, though still
susceptible to infection, are less likely to have symptomatic disease
[3].
In vivo von Willebrand Factor (VWF) biosynthesis is limited to
endothelial cells and megakaryocytes. VWF is produced and
released by vascular endothelial cells, and is frequently used as an
indicator of endothelial cell activation in vascular disorders such as
thrombotic thrombocytopenic purpura (TTP) and sepsis [4–6].
Published work has demonstrated that VWF plays a critical role in
primary haemostasis by mediating platelet adhesion to sites of
vascular injury [7,8]. Before newly synthesized VWF leaves the
endothelial cell, it undergoes endoproteolytic cleavage of its
propeptide. The processed VWF and propeptide are either
released constitutively or, following activation of the endothelium,
released through a regulated pathway. Upon stimulation, mature
VWF and propeptide are released in equimolar amounts and,
once in the blood, mature VWF and its propeptide become
completely dissociated and have different lifespans [9,10]. VWF
propeptide is important for intracellular trafficking and processing
of VWF [4,11,12] and is cleared from the circulation at a much
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hours. VWF, together with its propeptide, is stored within Weibel
Palade bodies [13] and exists as ultra large VWF multimers with a
half-life of 10–12 hours. The multimeric composition of VWF is a
critical determinant of its functional activity. Both mature VWF
and propeptide concentrations significantly increase upon acute
perturbation of the endothelium [14]. Since VWF propeptide has
a more rapid turnover than VWF, measurement of the
concentrations of both molecules in the peripheral blood allows
discrimination between chronic and acute phases of endothelial
cell activation in vivo.
In a prospective study of patients from Ghana with different
malaria presentations, we showed that patients with severe P.
falciparum infection had significantly increased plasma VWF and
propeptide levels, consistent with acute endothelial cell activation
[15]. Work has shown that elevated plasma VWF and
propeptide levels develop soon after the onset of a P falciparum
parasitaemia [16], indicating that acute endothelial cell activa-
tion constitutes an early feature of this infection. Indeed our
recent findings show that severe P. falciparum malaria is
associated with circulating ultra large VWF multimers [17],
consistent with acute endothelial cell activaton. We have also
demonstrated that rapid activation of endothelial cells enables P.
falciparum adhesion to platelet-decorated VWF strings [18], a
novel mechanism by which P. falciparum-infected erythrocytes
(IE) might sequester in vascular beds which do not express
appropriate host endothelial receptors. These findings together
suggest the possibility that the secretion of VWF by activated
endothelial cells may be a mechanism that enhances the severity
of P falciparum malaria.
Severe malaria is commonly misdiagnosed in Africa, because a
patient with severe disease of any cause may have a parasitaemia
that is coincidental and not responsible for the illness [19].
Malarial retinopathy is a set of retinal signs [20], some of which
are unique to malaria and, on the basis of post-mortem studies
[21], when identified in a comatose patient, greatly strengthen the
confidence with which the syndrome can be attributed to malaria.
In the current prospective study we investigated plasma VWF
and propeptide levels in paediatric malaria. We measured mature
VWF and propeptide concentrations in plasma samples collected
from children with P. falciparum parasitaemia who had severe
disease or uncomplicated febrile illness and controls without
parasitaemia. We used malarial retinopathy to differentiate
patients with definite cerebral malaria from those with encepha-
lopathy accompanied by parasitaemia.
Materials and Methods
1. Patient selection
The study was carried out at Queen Elizabeth Central Hospital
(QECH) in Blantyre, Malawi. Children with P falciparum
parasitaemia presenting with uncomplicated febrile illness or with
encephalopathy were recruited for the study. Controls were febrile
children without parasitaemia and well children undergoing
routine surgery. Children (mean age=33 months) were recruited
for both the control and index groups after their parents or
guardians had given written informed consent to their participa-
tion in the study. Clinical details were recorded for all cases at the
time of recruitment, and all subsequent analyses were carried out
blind to these details. All patients with malaria received standard
supportive and anti-malarial treatment.
Cerebral malaria cases. Patients (n=100) were recruited
when admitted with an initial clinical diagnosis of cerebral malaria
(CM), defined as a Blantyre Coma Score (BCS) of 2 or less [21],
with peripheral P. falciparum parasitaemia and no other identifiable
cause of coma [22]. CM children were examined for retinopathy
[20]. In nine CM children with retinopathy an additional sample
was collected at 48 hours, and in seven a further sample was
collected 30 days following admission at a follow up visit as part of
a separate study.
Mild malaria cases. Patients with mild malaria (MM) were
children attending the same hospital’s Paediatric Accident and
Emergency Unit (PAEU). These children were febrile and
parasitaemic, had no complications suggestive of severe malaria
[23], and were well enough to be managed at home (n=59).
Febrile controls without malaria. Children (6–60 months)
with a non-malaria febrile illness (NMFI) were recruited from
among attenders at the same PAEU. This group comprised
children not requiring admission, who had a documented febrile
illness (.37.5uC) with no malaria parasites on a single thick blood
film, a negative rapid diagnostic test for malarial antigens
(Paracheck, Orchid Biomedical Systems, Goa, India), and no
history of having taken any antimalarial medication in the
previous two weeks (n=32).
Healthy controls. These were well children with no febrile
illness (NFI) admitted for elective surgery (n=20). A Paracheck
malaria rapid antigen diagnostic test was performed on all controls
and only those negative were included in the analysis (n=17).
Adult controls. To develop a Malawian standard for VWF
and propeptide, and a normal range for a Malawian (adult)
population, we recruited 50 healthy Malawian adult blood donors
through the Malawi Blood Transfusion Services (MBTS). These
donors were negative for both human immunodeficiency virus
(HIV) by serology and for malaria by thick blood film microscopy
and rapid diagnostic test. Citrated plasma samples were pooled
together to provide a local standard.
2. Clinical measurements
Clinical details were taken using a research proforma at the time
of admission, and for children with CM through timed data
capture points during ward admission. Retinal examination in CM
was performed by one ophthalmologist with extensive previous
experience of observing malarial retinopathy. Mydriatic eyedrops
were used in all cases, and the retina was examined by both direct
and indirect ophthalmoscopy.
3. Laboratory measurements
For the measurements of plasma VWF and VWF propeptide in
hospital and emergency room patients and for the MBTS blood
donors, venous blood samples were collected in citrated tubes (1:9
vol/vol), and immediately placed at 4uC until spun. The 30 days
post-admission samples were collected in lithium heparin. Samples
were centrifuged and plasma was aliquoted and stored at 280uC
until analysed batchwise.
VWF and VWF propeptide concentrations were measured by
enzyme-linked immunosorbent assay (ELISA) as previously
described [23]. Pooled plasma from 40 adult Caucasian donors
containing 49 nM of VWF and 5.5 nM of VWF propeptide was
used as a standard on each plate. Plasma lactate was measured by
Lactate-Pro analyser. EDTA blood was used for preparing a
Fields stained thick blood film which was examined microscop-
ically to determine parasitaemia. Beckman Coulter Hmx
Hematology analyzer was used to measure haemoglobin and
platelet count. Children with CM were tested for HIV using two
rapid diagnostic test kits, rapid Uni-Gold HIV test (Trinity
Biotech PLC, Ireland) and Determine HIV rapid test (Abbott
Laboratories, USA).
Elevated VWF and Propeptide in Childhood Malaria
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e256264. Ethical approval
This study was approved by the ethics committees of the
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5. Statistical analysis
Data were analyzed using the GraphPad Prism v4.03 and SPSS
(version 18) statistical packages. As all of the continuous variables
had very positively skewed distributions, all analyses were
conducted using distribution-free statistical tests; results are
summarised using medians (ranges) unless otherwise stated.
Plasma concentrations of VWF and propeptide were compared
across the study sub-groups using the Kruskal-Wallis test with
Bonferroni correction for post-hoc multiple pairwise testing. The
Friedman test was used to compare median plasma concentrations
of VWF and propeptide in children during and after treatment.
Comparisons of groups based on malaria retinopathy, illness
outcome, HIV status and gender were made using the Mann-
Whitney U-test. Correlations between variables were estimated
using the Spearman correlation coefficient. Statistical significance
was set at the conventional 5% level for all analyses.
Results
Patients’ characteristics
A total of 100 children with CM were recruited, and 99
underwent ophthalmology examination, with 79 (79.8%) having
retinopathy. Of these, 13 children died, and nine were discharged
with clinically significant neurological deficits. The remaining
children responded to antimalarial drug therapy and made a full
recovery. The clinical and laboratory findings in different subsets
of children with and without falciparum malaria are summarized in
Table 1.
Plasma VWF and propeptide concentrations in Malawian
children
The median plasma concentrations of VWF and propeptide of
the NFI controls were 37.1 (9.3–62.1) nM and 3.4 (1.0–30.6) nM,
respectively (Figure 1). These values are within the normal range
of healthy Caucasians [23,24] and local healthy Malawians
(median: 42.9 (20.4–110.6) nM and 5.1 (1.8–15.0) nM for VWF
and propeptide, respectively). In NMFI children, median VWF
and propeptide levels were 72.3 (20.4–142.7) nM and 9.3 (2.3–
22.3) nM, respectively, values that were significantly different from
normal values for healthy Caucasian and Malawian subjects
(p,0.001 for both variables).
Median plasma concentrations of both VWF and propeptide at
admission were significantly higher in children with both cerebral
and mild malaria when compared with the non-malarial control
groups (p,0.001 both variables) - and were also significantly
higher in children with cerebral malaria compared to those with
mild malaria (p,0.001 for both variables, Figure 1).
Plasma VWF and propeptide concentrations during and
after treatment
A subset of cerebral malaria children (n=7) was studied
prospectively to relate plasma VWF and propeptide levels at the
time of admission to plasma levels 48 hours and 30 days after the
start of treatment. At 48 hours, median plasma VWF and
propeptide levels had dropped significantly from 189.9 (101.0–
378.4) to 112.9 (59.8–192.0) nM and 19.1 (11.6–31.0) to 12.6 (6.7–
22.2) nM, respectively (p=0.016 for both variables, Figure 2).
After recovery (30 days after receiving therapy), median VWF
and propeptide levels in this subset of children were significantly
lower than at admission (p=0.016 for both variables)or at 48 hours
(p=0.016 for VWF, p=0.031 for propeptide) (Figure 2), with
median plasma levels at 30 days similar to normal levels in controls.
Table 1. Clinical and laboratory characteristics by diagnosis of children with and without Plasmodium falciparum malaria –
medians (ranges).
CM Cerebral Malaria MM Mild malaria
NMFI Non-malaria
febrile illness controls
NFI Non-febrile
illness controls
retinopathy positive retinopathy negative
Sample size 79 20 59 32 17
Sex
1 female 32 (40.5%) 11 (55.0%) 26 (44.1%) 12 (38.7%) 8 (47.1%)
male 47 (59.5%) 9 (45.0%) 33 (55.9%) 19 (61.3%) 9 (52.9%)
Age (months)
2 34.5 (8.0–86.0) 36.5 (17.0–164.0) 24.0 (3.0–60.0) 23.5 (6.0–60.0) 23.0 (6.0–48.0)
Lactate (nM) 6.9 (1.1–18.9) 5.1 (1.2–21.4) n.t. n.t. n.t.
Platelets (10
4/ml)
3 5.2 (0.5–26.6) 12.5 (0.6–54.5) 13.8 (2.9–31.6) 34.1 (27.4–58.0) n.t.
Haemoglobin (g/dl)
4 6.1 (2.5–10.0) 9.2 (4.3–12.9) 7.9 (3.6–12.8) 10.3 (7.0–12.5) n.t.
Parasitaemia (10
3/ml)
5 51.5 (0.1–1149.4) 58.8 (0.2–725.9) n.t. n.t. n.t.
VWF (nM) 191.1 (40.5–484.3) 171.9 (110.1–427.2) 117.2 (64.4–355.3) 72.3 (20.4–142.7) 37.1 (9.3–62.1)
VWFpp (nM) 28.4 (4.8–107.5) 33.2 (9.0–80.0) 18.3 (5.1–53.2) 9.3 (2.3–22.3) 3.4 (1.0–30.6)
n.t.: not tested.
1not recorded for 1 child in NMFI group.
2not recorded for 1 child in CM retinopathy positive group.
3not recorded for 5 children in CM retinopathy positive group, 1 child in CM retinopathy negative group, 10 children in MM group and 22 children in NMFI group.
4not recorded for 10 children in MM group and 22 children in NMFI group.
5not recorded for 2 children in CM retinopathy positive group and 1 child in CM retinopathy negative group.
Normal range for lactate: 0.7–2.1 nM.
doi:10.1371/journal.pone.0025626.t001
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PLoS ONE | www.plosone.org 3 November 2011 | Volume 6 | Issue 11 | e25626Figure 1. Plasma concentration of von Willebrand factor (VWF) and VWF propeptide in various subsets of children with and
without Plasmodium falciparum malaria. Graphs showing median and scatter of plasma VWF and VWF propeptide levels in children with cerebral
malaria (CM) and mild malaria (MM), and in non-malaria febrile illness (NMFI) and non-febrile illness (NFI) controls as measured by ELISA (Kruskal-
Wallis, *** P,0.001; **P,0.01 after Bonferroni correction for post-hoc multiple pairwise testing). Dotted lines indicate median levels in local healthy
Malawian adults.
doi:10.1371/journal.pone.0025626.g001
Figure 2. Plasma concentration of VWF and propeptide in Plasmodium falciparum cerebral malaria patients during and after
treatment. Plasma levels of VWF and VWF propeptide were measured at admission, 2 days and 30 days post-treatment in a cohort of retinopathy
positive children with cerebral malaria (Friedman Test, *P,0.05). Dotted lines indicate median levels in local healthy Malawian adults.
doi:10.1371/journal.pone.0025626.g002
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cerebral malaria, with and without retinopathy
VWF and propeptide plasma concentrations were compared
between cerebral malaria children with retinopathy and those
without retinopathy. Median concentrations and ranges of the two
proteins were similar in these two groups (p=0.832 and p=0.143,
respectively, Figure 3).
VWF and propeptide levels in retinopathy-positive CM
according to clinical outcome
To determine whether VWF and propeptide are prognostic
markers for death in confidently-diagnosed paediatric cerebral
malaria, we measured plasma protein levels in retinopathy positive
children who recovered and those who died. Median plasma VWF
levels did not differ significantly between these two groups: survived:
192.0 (40.5–484.3), died 176.5 (81.1–440.1); p=0.873. Similarly,
median propeptide levels did not differ significantly: survived 28.4
(5.3–107.5), died 26.6 (4.8–66.0); p=1.000 (Figure 4).
Other clinical measurements
The median circulating platelet count differed significantly
between the NMFI group and the cerebral and mild malaria
groups (p,0.001 for both comparisons, Table 1). Platelet counts
were significantly lower in children with cerebral malaria than in
those with mild malaria (p,0.001). Platelet count did not correlate
with either VWF or VWF propeptide in children with retinopathy
positive cerebral malaria (rho=20.165, p=0.160 and
rho=20.074; P=0.533, respectively). Children with retinopathy
positive cerebral malaria had lower median (range) platelet counts
52,000 (5000–266,000) than those without retinopathy 125,000
(6000–545,000) (Mann Whitney U Test p=0.056).
Of the 69 children with cerebral malaria and positive
retinopathy for whom HIV status was known, 59 were sero-
negative, and ten had positive HIV serology. Median concentra-
tions in each for VWF were 196.6 (54.3–484.3) and 153.5 (48.5–
247.4) nM respectively, and for propeptide were 30.2 (4.8–107.5)
and 25.4 (6.4–44.5) nM (p=0.059 and p=0.137 respectively).
Neither VWF nor propeptide concentration correlated with
plasma lactate levels (rho=20.198; p=0.080 and rho=20.020;
p=0.862 respectively). There was no significant difference in
median VWF or propeptide concentration between children with
lactic acidosis (plasma lactate .5 nM) (VWF: 224.5 (63.4–378.4);
propeptide: 26.4 (4.8–50.7) and those with plasma lactate ,5n M
(VWF: 185.0 (40.5–484.3); propeptide: 28.4 (5.3–107.5) (p=0.340
and p=0.504 respectively). Median VWF and propeptide levels
did not differ between male children (n=47; VWF: 202.5 (40.5–
484.3); propeptide: 26.6 (4.8–107.5)) and female children (n=32;
VWF: 182.0 (54.3–378.4); propeptide: 29.9 (11.6–77.4)) children
(p=0.418 and p=0.168 respectively).
Discussion
We studied the patterns of increase in the plasma concentrations
of VWF and propeptide in Malawian children with mild and
severe malarial disease in order to assess the relationship of these
biomarkers with disease severity. Our findings show that VWF and
propeptide levels are markedly elevated in patients with retinop-
athy positive cerebral malaria but less so in mild malaria (Figure 1).
In some patients VWF and propeptide levels were even higher
than the levels published in known cases of fulminant vascular
disorders such as TTP and sepsis [14]. Our observations
corroborate those of Hollestelle et al., [15] that circulating
concentrations of both VWF and its propeptide are specifically
and markedly raised in patients with P. falciparum infection, and
that VWF and propeptide levels are markers of endothelial
activation in falciparum malaria, at higher levels than seen in other
infections, suggesting a specific perturbation in malaria.
Figure 3. Plasma concentration of VWF and propeptide in severe Plasmodium falciparum malaria patients with and without
retinopathy. Graphs showing median and scatter of plasma VWF and VWF propeptide levels in cerebral malaria children with (+) and without (2)
retinopathy as measured by ELISA (Mann Whitney U test, p=0.832 and p=0.143, respectively).
doi:10.1371/journal.pone.0025626.g003
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significant decline in both VWF and propeptide levels towards
normal values in healthy Malawian controls (Figure 2). Since levels
of VWF returned to normal population values following infection,
inherent levels of VWF do not appear to be raised in these
children. One surprising observation different from that seen in
Ghana [15] was that neither VWF nor propeptide levels correlated
with blood lactate levels in our cohort, with no significant
difference in VWF and propeptide levels between children with
hyperlactataemia (lactate .5 nM) and those with blood lactate
concentrations ,5 nM. Plasma lactate has been reported to be of
pathophysiological and prognostic significance in both children
and adults with cerebral malaria [25,26].
A novel aspect of this study is the assessment of plasma VWF
and propeptide levels in cerebral malaria cases confirmed on the
basis of malarial retinopathy. The presence of malarial retinopathy
in histopathological studies of fatal paediatric cerebral malaria has
been reported to have a positive predictive value of 95% and a
specificity of 90% for the detection of histopathologically
confirmed cerebral malaria in parasitaemic patients [27].
Therefore in research studies it is the best technique yet available
to confirm that a patient has cerebral malaria, and exclude from
the cohort those who clinically appear to have cerebral malaria but
might actually have another underlying cause for their coma.
The observation that plasma VWF and propeptide levels were
not significantly different between children who died and those
who recovered (Figure 4) suggests that these proteins are not
prognostic markers of death in cerebral malaria. Recent
observations have shown that that, in addition to other
biomarkers, VWF propeptide is a good marker of cerebral malaria
in fatal paediatric malaria and that both VWF and propeptide are
good at differentiating between cerebral and mild malaria [28,29].
The surprising result from our study comes from the comparison
of VWF and propeptide levels in cases defined clinically as
cerebral malaria but divided into retinopathy positive and
negative. Our assumption is that the retinopathy negative cases
represent very sick children in a coma but where the parasitaemia
is incidental, rather than the underlying cause of pathology. The
similar levels of VWF and propeptide in both categories suggest
that VWF levels are not able to discriminate between cerebral
malaria and coma due to other causes in the presence of malaria
parasites. One possible explanation for this would be that
increased VWF levels are seen generally on infection by the
malaria parasite, as demonstrated in mild malaria cases but a
second component not linked directly to parasitaemia but perhaps
linked to general pro-inflammatory processes or endothelial
dysfunction may be responsible for the further increase seen in
cerebral malaria. Thus the very high levels of VWF and
propeptide seen here might be markers of severe pathology (e.g.
coma) with malaria infection rather than specifically cerebral
malaria. Further studies comparing parasitaemic and non-
parasitaemic severe disease cases will be required to discriminate
between these components.
Platelets were significantly lower in patients with cerebral
malaria than in those with mild malaria. Platelet changes have
long been known in malaria, thrombocytopenia being a usual
feature of plasmodial infections. Several independent lines of
evidence suggest that platelets play a role in the pathogenesis of
cerebral malaria: (1) postmortem studies in African children with
cerebral malaria have revealed that in some cases platelets co-
Figure 4. Plasma concentration of VWF and propeptide in Plasmodium falciparum cerebral malaria patients with retinopathy. Graphs
showing median and scatter of plasma VWF and VWF propeptide levels in retinopathy positive children with cerebral malaria who died (Died) or
recovered (Recovered) as measured by ELISA (Mann Whitney U test, p=0.873, p=1.000, respectively).
doi:10.1371/journal.pone.0025626.g004
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suggesting that platelets can play a role in the pathogenesis of
cerebral malaria; (2) in vitro studies have demonstrated platelet-
mediated IE adhesion to TNF-activated brain endothelium by
acting as a bridge between the endothelium and IE [30], a
mechanism that allows CD36-mediated binding in microvessels
where CD36 expression is known to be low or irregular [31]; (3)
platelets have been implicated in IE clumping associated with
pathogenesis of malaria [32]. Also our recent studies in Malawi
have established a novel mechanism by which IE adhere via
platelet decorated ultra large VWF strings on activated endothe-
lium. Large VWF multimers in plasma bind activated platelets
with ,100 fold higher affinities compared to monomers [33,34].
As well as enabling IE to sequester in vascular beds which do not
express appropriate IE receptors, this novel mechanism also
provides a link between the observed high levels of VWF in
malaria and platelet-mediated IE adhesion to brain endothelium.
This mechanism may explain the low platelet count observed in
children with malaria, and in particular retinopathy positive
cerebral malaria patients in our cohort due to extensive platelet
sequestration in the vasculature. Furthermore the malaria parasite
may be able to modulate the production of VWF through release
of an orthologue of Translationally Controlled Tumor Protein
(PfTCTP), promoting histamine release from basophils (in vitro),
and present in early asymptomatic infection in humans (in vivo)
[34].
In summary, we have confirmed that plasma VWF and
propeptide levels are markedly elevated in both cerebral and mild
paediatric malaria, discriminate between these two conditions and
that in cerebral malaria these normalize upon recovery. It is not
possible to say whether VWF and VWF propeptide are more
markedly elevated specifically in retinopathy positive cerebral
malaria than other central nervous system (CNS) severe illnesses in
the presence of malaria infection. Further work on the specificity
and sensitivity of VWF and VWF propeptide is therefore required
to ascertain their role as prognostic biomarkers for malaria disease
severity.
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